Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

Daver Naval G.; Pollyea Daniel A.; Garcia Jacqueline S.; Jonas Brian A.; Yee Karen W. L.; Fenaux Pierre; Assouline Sarit; Vey Norbert; Olin Rebecca; Roboz Gail J.; Tafuri Agostino; Visani Giuseppe; Kirschbrown Whitney; Green Cherie; Ma Connie; Dail Monique; Wang Jue; Ott Marion G.; Mobasher Mehrdad; Phuong Patrick; Hong Wan-Jen; Konopleva Marina Y.; Andreeff Michael

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

【24h】

Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

机译：BCL2抑制剂venetoclax（Hever）加上MDM2抑制剂Idasanutlin（idasa）的安全性，疗效，药代动力学（PK）和生物标志物分析，患者（PTS）（R / R）AML：A相IB，非随机化，开放 -Label学习

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共5页
作者
Daver Naval G.; Pollyea Daniel A.; Garcia Jacqueline S.; Jonas Brian A.; Yee Karen W. L.; Fenaux Pierre; Assouline Sarit; Vey Norbert; Olin Rebecca; Roboz Gail J.; Tafuri Agostino; Visani Giuseppe; Kirschbrown Whitney; Green Cherie; Ma Connie; Dail Monique; Wang Jue; Ott Marion G.; Mobasher Mehrdad; Phuong Patrick; Hong Wan-Jen; Konopleva Marina Y.; Andreeff Michael;
展开▼
作者单位

MD Anderson Canc Ctr Dept Leukemia Houston TX USA;

Univ Colorado Denver CO 80202 USA;

Dana Farber Canc Inst Boston MA 02115 USA;

Univ Calif Davis Davis CA 95616 USA;

Univ Hlth Network Princess Margaret Canc Ctr Toronto ON Canada;

Univ Paris Diderot Hop St Luc Paris France;

Jewish Gen Hosp Montreal PQ Canada;

Inst Paoli Calmettes Dept Hematol Marseille France;

Univ Calif San Francisco San Francisco CA USA;

Cornell Univ Weill Cornell Med New York NY 10021 USA;

Univ Roma Rome Italy;

Osped San Salvatore Pesaro Italy;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

F Hoffmann La Roche Ltd Basel Switzerland;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

MD Anderson Canc Ctr Houston TX USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献

1. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study [J] . Daver Naval G., Pollyea Daniel A., Garcia Jacqueline S., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：BCL2抑制剂venetoclax（Hever）加上MDM2抑制剂Idasanutlin（idasa）的安全性，疗效，药代动力学（PK）和生物标志物分析，患者（PTS）（R / R）AML：A相IB，非随机化，开放 -Label学习
2. Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440) [J] . Stilgenbauer Stephan, Morschhauser Franck, Wendtner Clemens-Martin, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：venetoclax（Ven）与苯顿蛋白（b）加里妥昔单抗（r）或obinutuzumab（g）组合的安全性和有效性与先前未处理的慢性淋巴细胞白血病（CLL）中的患者（pts）中的：结果来自IB研究的结果（GO28440）
3. Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study [J] . Greil Richard, Fraser Graeme, Leber Brian, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：尿嘧啶（SB）在尿嘧啶复发/难治（R / R）慢性淋巴细胞白血病（CLL）中的IBR-NAIVIVE患者治疗后Ibrutinib（SEN）治疗的疗效和安全性：来自Murano研究的患者的随访
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Efficacy Safety and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized Open-label Phase 2 Study [O] . Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, -1

机译：在复发/难治性急性髓性白血病中对阿扎胞苷和尼古鲁单抗反应的功效安全性和生物标志物：一项非随机开放标签的2期研究
6. A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas [O] . 2014

机译：一项Ib / II期开放标签研究，旨在评估MEDI-551联合免疫调节疗法对复发或难治性侵袭性B细胞淋巴瘤患者的安全性和有效性

Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

著录项

相似文献

相关主题

期刊订阅